Usama Gergis MD,MBA | Jefferson Health

Dr. Usama Gergis, MD

Claim this profile

Thomas Jefferson University

Studies Cancer
Studies Hematologic Malignancies
13 reported clinical trials
29 drugs studied

Area of expertise

1Cancer
Usama Gergis, MD has run 4 trials for Cancer. Some of their research focus areas include:
HLA-A negative
HLA-A positive
HLA positive
2Hematologic Malignancies
Usama Gergis, MD has run 3 trials for Hematologic Malignancies. Some of their research focus areas include:
HLA positive
HLA negative

Affiliated Hospitals

Image of trial facility.
Thomas Jefferson University
Image of trial facility.
Sidney Kimmel Cancer Center At Thomas Jefferson University

Clinical Trials Usama Gergis, MD is currently running

Image of trial facility.

Reduced-Intensity Conditioning

for Blood Cancers

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation therapy uses high energy sources to kill cancer cells and shrink tumors while chemotherapy drugs like fludarabine and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study evaluates whether a two-step approach with lower-intensity regimens of these treatments prior to HSCT reduces the rate of TRM.
Recruiting1 award Phase 28 criteria
Image of trial facility.

GM T Cell Therapy Long-Term Follow-Up

for Cancer

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Recruiting1 award Phase 2 & 3

More about Usama Gergis, MD

Clinical Trial Related8 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Usama Gergis, MD has experience with
  • Cyclophosphamide
  • Mycophenolate Mofetil
  • Tacrolimus
  • Total-Body Irradiation
  • Chemotherapy Agents
  • Fludarabine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Usama Gergis, MD specialize in?
Is Usama Gergis, MD currently recruiting for clinical trials?
Are there any treatments that Usama Gergis, MD has studied deeply?
What is the best way to schedule an appointment with Usama Gergis, MD?
What is the office address of Usama Gergis, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security